* The report reviews pipeline therapeutics for End-Stage Kidney Disease (
End-Stage Renal Disease or ESRD) by companies and universities/research institutes based on information derived from company and industry-specific sources
Inflammation in
end-stage renal disease: could it be treated.
Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in
end-stage renal disease. Circulation 1998;97: 138-41.
End-stage renal disease was 14-fold higher in the cohort with hypertensive disorders.
At the other end of the spectrum are the people who have progressed to
end-stage renal disease, which is basically complete kidney failure.
For students, patients, and doctors, this text updates readers on current therapies for
end-stage renal disease as of 2009, as well as therapy of the future.
Predictive value of cardiac troponin I and T for subsequent death in
end-stage renal disease. Circulation, 106, 2941-2945.
Patients with
end-stage renal disease (ESRD) have an increase risk of cardiac mortality and morbidity.
Comment: Patients with
end-stage renal disease have an impaired capacity to excrete phosphorus and are at risk of developing hyperphosphatemia, which can increase morbidity and mortality.
End-stage renal disease occurs when the patients' kidneys have failed to the point where dialysis or a kidney transplant is needed.
In recent decades, kidney replacement therapy such as haemodialysis, peritoneal dialysis, and kidney transplantation have lengthened the life of many patients with
end-stage renal disease (Reimer et al., 2000).
The conditions are certain neurologic disorders, stroke, chronic alcohol and other drug dependence, certain autoimmune disorders, cancer excluding precancer conditions, certain cardiovascular disorders, chronic heart failure, dementia, diabetes mellitus, end-stage liver disease,
end-stage renal disease requiring dialysis, certain severe hematologic disorders, HIV/AIDS, certain chronic lung disorders, and certain chronic and disabling mental health conditions.
